An Intense and Short-Lasting Burst of Neutrophil Activation Differentiates Early Acute Myocardial Infarction from Systemic Inflammatory Syndromes

Norma Maugeri1*, Patrizia Rovere-Querin1, Virgilio Evangelista2, Cosmo Godino1, Monica Demetrio3, Mattia Baldini1, Filippo Figini1, Giovanni Coppi1, Massimo Slavich1, Marina Camera3, Antonio Bartorelli3, Giancarlo Marenzi3, Lara Campana1, Elena Baldissera1, Maria Grazia Sabbadini1, Domenico Cianflone1, Elena Tremoli3, Armando D’Angelo1, Angelo A. Manfredi1, Attilio Maseri1,4

1 Università Vita-Salute San Raffaele and San Raffaele Scientific Institute, Milano, Italy, 2 Istituto Consonzio Mario Negri Sud, Santa Maria Imbaro, Italy, 3 Centro Cardiologico Monzino, Milano, Italy, 4 Heart Care Foundation, Florence, Italy

Abstract

Background: Neutrophils are involved in thrombus formation. We investigated whether specific features of neutrophil activation characterize patients with acute coronary syndromes (ACS) compared to stable angina and to systemic inflammatory diseases.

Methods and Findings: The myeloperoxidase (MPO) content of circulating neutrophils was determined by flow cytometry in 330 subjects: 69 consecutive patients with acute coronary syndromes (ACS), 69 with chronic stable angina (CSA), 50 with inflammation due to either non-infectious (acute bone fracture), infectious (sepsis) or autoimmune diseases (small and large vessel systemic vasculitis, rheumatoid arthritis). Four patients have also been studied before and after sterile acute injury of the myocardium (septal alcoholization). One hundred thirty-eight healthy donors were studied in parallel. Neutrophils with normal MPO content were 96% in controls, >92% in patients undergoing septal alcoholization, 91% in CSA patients, but only 35 and 30% in unstable angina and AMI (STEMI and NSTEMI) patients, compared to 80%, 75% and 2% of patients with giant cell arteritis, acute bone fracture and severe sepsis. In addition, in 32/33 STEMI and 9/21 NSTEMI patients respectively, 20% and 12% of neutrophils had complete MPO depletion during the first 4 hours after the onset of symptoms, a feature not observed in any other group of patients. MPO depletion was associated with platelet activation, indicated by P-selectin expression, activation and transactivation of leukocyte β2-integrins and formation of platelet neutrophil and -monocyte aggregates. The injection of activated platelets in mice produced transient, P-selectin dependent, complete MPO depletion in about 50% of neutrophils.

Conclusions: ACS are characterized by intense neutrophil activation, like other systemic inflammatory syndromes. In the very early phase of acute myocardial infarction only a subpopulation of neutrophils is massively activated, possibly via platelet-P selectin interactions. This paroxysmal activation could contribute to occlusive thrombosis.

Introduction

Platelet and endothelial activation, associated with plaque instability, are important mechanisms in the pathogenesis of acute coronary syndromes (ACS) [1–5]. Activated platelets and endothelium interact with circulating leukocytes [6–16], which are also activated in ACS generating a positive feedback loop.

Activated platelets and neutrophils appear in the peripheral circulation after the onset of acute symptoms of infarction, but gradually disappear during the subsequent hours [1,10,11,17] at variance with platelet-monocyte heterotypic aggregates, which persist longer [1,17]. Neutrophils also represent the major cellular component of coronary thrombi [2,4,13,18,19] and their activation is associated with massive myeloperoxidase (MPO) release [3,10,11,20] [21–22]. In turn the peak concentration of circulating MPO is reached in the very early hours after infarction [3] and MPO is found in unstable coronary plaques at post mortem [2,4,13,19].

Given the short life of circulating neutrophils the release of their MPO content can only reflect the effects of stimuli active during the previous 6–8 hours of their life time. Thus, measurement of neutrophil MPO content at different times after the onset of symptoms could provide information on the time-course as well as clues on distinctive features of inflammatory stimuli associated

Citation: Maugeri N, Rovere-Querin P, Evangelista V, Godino C, Demetrio M, et al. (2012) An Intense and Short-Lasting Burst of Neutrophil Activation Differentiates Early Acute Myocardial Infarction from Systemic Inflammatory Syndromes. PLoS ONE 7(6): e39484. doi:10.1371/journal.pone.0039484

Editor: Nikolaos Frangogiannis, Albert Einstein College of Medicine, United States of America

Received January 31, 2012; Accepted May 21, 2012; Published June 25, 2012

Copyright: © 2012 Maugeri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work has been supported by the Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR) to Attilio Maseri, Patrizia Rovere-Querin, Angelo A. Manfredi and Maria G. Sabbadini and by the Ministero della Salute to Angelo A. Manfredi and Patrizia Rovere-Querin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: maugeri.norma@hsr.it
with coronary instability. We have studied neutrophil MPO content and its relation to platelet and monocyte activation in patients with segment T elevation myocardial infarction (STEMI), with non elevation myocardial infarction (NSTEMI) and with unstable angina, sampled before any therapeutic intervention. As controls, we studied patients with chronic stable angina (CSA) before and after coronary angioplasty. In addition, for comparison, we have studied patients with well established inflammatory conditions: Giant Cell Arteritis, Polymyalgia Rheumatica, ANCA-associated small-vessel vasculitis, rheumatoid arthritis, severe sepsis, and acute traumatic bone fractures.

We have observed a large percentage of the average MPO content in most patients but not in matched healthy controls or in subject with CSA. In addition, we have identified a distinctive feature of neutrophil activation in the very early hours after acute myocardial infarction, reflecting a paroxysmal response to an intense, short lasting trigger. Platelet P-selectin expression was correlated with neutrophil activation, which in turn may contribute to thrombus formation [15,16,23].

Materials and Methods

Patients and Controls

Patients and healthy donors (330 consecutive subjects) were studied in blind. We studied 69 patients with acute coronary syndromes before any therapeutic intervention: 54 with acute myocardial infarction (AMI) (34 with STEMI and 20 with NSTEMI), and 15 patients with unstable angina, studied less than 12 hours (mean±SD 4.0 hours ±30 min) from the onset of symptoms. Unstable angina was defined as typical chest pain at rest without elevation of creatine kinase or troponin I. AMI was defined on the basis of chest pain at rest, ECG recording and elevation of creatine kinase or troponin I. STEMI patients were all those that had electrocardiography evidence of at least 2 mm in at least 2 consecutive leads of ST segment elevation. From each patient, clinical data were obtained, including age, sex, hypercholesterolemia (total plasma cholesterol concentration >200 mg/dl or ongoing lipid-lowering drug therapy), hypertension (history of elevated blood pressure requiring antihypertensive therapy), diabetes mellitus (history of diabetes or fasting plasma glucose >126 or >200 mg/dl 2 h after a meal), active smoking (>5 cigarettes daily), and overweight/obesity (body mass index >25 kg/m²). C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). To analyze the time course of neutrophil activation in acute coronary syndromes, 36 AMI patients and 10 patients with unstable angina were again studied at 24, 36 and 48 hours after Percutaneous Coronary Intervention (PCI). We also studied 69 patients with chronic stable angina (CSA) at the time of coronary angiography: 15 of them were re-investigated 4 hours after PCI. All CSA patients had evidence of myocardial ischemia during stress tests or of angina recurrence. PCI was performed in case of: i) angiographic evidence of critical stenosis (>75%) or ii) lesions with stenosis <75% but characterized by a reduced myocardial fractional flow reserve (cut-off <0.75). Four patients with hypertrophic obstructive cardiomypathy were studied before and four hours after absolute ethanol had been introduced into a major septal artery to create a controlled septal infarction [24]. We also studied five patients with bone fractures, seven patients with severe sepsis, 11 patients with ANCA-associated small-vessel vasculitis, eight patients with polymyalgia rheumatica, eight patients with giant cell arthritis and eleven patients with rheumatoid arthritis previous any treatment, classified according to the American Rheumatism Association 1987 revised criteria [25]. Patient clinical and demographic characteristics are summarized in Tables 1, 2 and 3. In parallel, 138 healthy donors were also studied (Table S1). In all cases exclusion criteria were: age <18 years, serum creatinine >2 mg/dl, anemia and history of cancer. All patients and controls signed an informed consent form (see ethics statement).

Blood Sampling and Processing

Venous blood was obtained using a 19-gauge butterfly. Blood was first drawn in a vacutainer tube to obtain serum followed by the collection of 3 mL into a tube containing sodium citrate and a cocktail of antiproteases (sodium EDTA, N-ethylmaleimide and aprotinin) used to study the neutrophil MPO content and cellular markers of activation by flow cytometry and confocal microscopy as previously described [9,10,11,26]. All determinations were performed in blind for the laboratory operators.

Reagents and Monoclonal Antibodies (mAbs)

Thrombofilix, mAbs against human CD14 (clone RMO52), human CD42a (platelet glycoprotein Ib, clone SZ2), human CD45 (clone J33), CD61 (platelet glycoprotein IIIa, clone SS2), human CD66b (clone 80H3), and human MPO (clone CLB-MPO-1) and the isotype-matched control mAbs (clone 679.1Mc7) were from Instrumentation Laboratories (Milan, Italy). FACs Lysing Solution mAbs against human P-selectin

Table 1. Characteristics of patients with coronary artery diseases.

|                | UA  | AMI | CSA |
|----------------|-----|-----|-----|
| Age, median (range) | 61.5 (48–70) | 61.7 (42–71) | 60.1 (45–72) |
| Sex: M/F      | 12/3 | 47/7 | 44/15 |
| CRP (mg/L)    | 4.0±0.3 | 4.8±0.8 | 1.2±0.3 |
| ESR (mm/h)    | 2.1±0.4 | 15.8±1.6 | 2.3±0.3 |
| Initial troponin I | 0.2±0.1 | 1.2±0.2 | n.a. |
| Peak troponin I | n.a. | 30.6±6.6 | n.a. |

| Risk Factors          |                |                |
|-----------------------|----------------|
| Cholesterol (mg/dL)   | 198.1±10.3     | 203.0±7.11     |
| Diabetes              | 2/15           | 4/54           |
| Hypertension          | 3              | 24             |
| Current smoking       | 5              | 24             |
| Obesity               | 3              | 6              |

N° of involved coronary arteries: % patients

|         |  |  |
|---------|----------|
| 0       | 25%      | 12%      | 0%  |
| 1       | 25%      | 36%      | 10% |
| 2       | 25%      | 32%      | 30% |
| 3       | 25%      | 20%      | 60% |

Demographic and clinical data are referred to the time of blood sample collection. CABG: Coronary Artery Bypass Graft. PCI: Percutaneous Coronary Intervention.
Table 2. Characteristics of patients with systemic inflammatory syndromes.

|                        | ANCA-associated small-vessel vasculitis | Giant Cell Arteritis | Polymyalgia rheumatica | Rheumatoid Arthritis |
|------------------------|----------------------------------------|----------------------|------------------------|----------------------|
| n                      | 11                                     | 8                    | 8                      | 11                   |
| Sex M/F                | 9/11                                   | 2/6                  | 2/6                    | 4/7                  |
| Age (years)            | 49.5 (36–78)                           | 71 (63–87)           | 70 (64–81)             | 59.5 (32–78)         |
| Disease duration (months) | 108±11.1                             | 10.5±2.2             | 29.4±6.2               | 23.9±8.9             |
| CRP (mg/L)             | 17.8±5.5                               | 11.5±2.5             | 13.3±3.1               | 32.2±13.6            |
| ESR (mm/h)             | 37.1±11.3                              | 32.8±4.1             | 40.4±8.2               | 44.6±11.4            |
| Disease activity (active n, %) | 8 (72.7%)                           | 6 (75%)              | 5 (62.5%)              | 8 (72.7%)            |
| Prednisone (mg/day)    | 19.1±5.1                               | 12.9±2.5             | 4.1±1.8                | 1.3±0.7              |
| Immunosuppressive drugs (n) |                                  |                      |                        |                      |
|                        | Cyclophosphamide (1)                   | Azathioprine (2)     | Methotrexate (1)       | –                    |
|                        | EN (11)                                | Headache (4)         | Myalgias (8)           | 11 Arthritis (1)     |
|                        | Lung nodules (5)                       | Myalgias (1)         | Aortitis (1)           | Bone erosions (5)    |
|                        | PNS (5)                                | Past optic nerve ischemia (2) |                        | Lung nodules (1)     |
|                        | NEPH (4)                               |                       |                        |                      |
|                        | Arthritis (4)                          |                       |                        |                      |
|                        | Cranial nerve neuritis (1)             |                       |                        |                      |
|                        | Orchitis (1)                           |                       |                        |                      |

Demographic and clinical data are referred to the time of blood sample collection. If not otherwise specified, means ± SEM are shown.

**Number of patients with disease-related organ involvement. ENT = ear, nose, throat; PNS = peripheral nervous system.

*Number (%) of patients with active disease (as assessed by the Rheumatologist on the basis of symptoms, inflammatory markers and, when available for the specific disease, disease activity scores).

doi:10.1371/journal.pone.0039484.t002

Table 3. Characteristics of septic patients.

| Patient/sex/age (years) | primary infection | cultures (microorganism/ material) | Shock (lactate) | Organ Involvement (present) | CRP (mg/L) | organ involvement (following) | outcome *** |
|-------------------------|-------------------|-------------------------------------|----------------|-----------------------------|------------|-------------------------------|-------------|
| 1/F/60                  | pneumonia         | S. aureus/blood                     | + (3.52)       | Res, Ren, Hep               | 277        | (DIC)                         | A           |
| 2/F/69                  | diverticulitis    | Staphylococcus spp/blood            | –              | –                           | 473        | –                             | A           |
| 3/F/86                  | colitis           | C. difficile/fecies                 | –              | –                           | 32.9       | –                             | A           |
| 4/M/63                  | bilateral pneumonia | S. marcescens/bronchoalveolar fluid | + (2.57)       | Ren                         | 204        | HEP, DIC                       | D           |
| 5/F/81                  | pneumonia         | S. aureus/bronchoalveolar fluid + blood | –             | Res, Ren                    | 141        | –                             | D           |
| 6/F/79                  | urinary tract infection | P. aeruginosa/ blood | + (2.90)     | Ren, Hep                     | 225        | –                             | A           |
| 7/M/82                  | aspiration pneumonia | E. coli/bronchoaspirate + blood     | +              | Resp                        | 220        | (DIC)                         | D           |

When not otherwise specified, demographic and clinical data are referred to the time of blood sample collection, and means ± SEM values are shown for each group; + : present; – : absent; **septic shock: when present, lactate concentration (mmol/L) is shown in brackets; * involved organs at the time of blood sample collection (present) or additional organ involvement in the following 3 days (following); Res: respiratory failure; Ren: renal failure, HEP: hepatic failure; DIC = Disseminated Intravascular Coagulation; ***outcome A: alive, D: dead.

doi:10.1371/journal.pone.0039484.t003
forward/scatter characteristics within the CD45+ population, comprising >99% CD66b+ and <1% CD14+ events. The normal range of the neutrophil MPO content was defined on the basis of the results obtained in 30 healthy subjects. In order to establish the background level of MPO-associated fluorescence after complete MPO depletion, the neutrophil MPO content was also assessed after stimulation of whole blood samples with fMLP (0.5 μM) in the presence of cytochalasin B (2.5 μg/mL) to induce the full release of neutrophil azurophilic granules content [28]. We used the intermediate range of MPO-associated MFI to define neutrophils with low MPO content. (Figure S1). Platelet leukocyte heterotypic aggregates, platelet P-selectin, leukocyte β2 upregulation and transactivation as well as leukocyte MRP8/14 expression were measured as previously described [9,10,11,26]. Analysis of samples was with a FC500, Beckman-Coulter.  

Animal Model

Whole blood from female C57BL/6N mice (wild type) or from C57BL/6-P-selectin (P-sel−/−) was obtained, processed and activated as described [10,26]. Platelets were injected in the tail vein of wild type mice. After 1, 2, 3, and 24 hours blood was obtained from the tail. The neutrophil MPO content and platelet-neutrophil heterotypic were determined by flow cytometry as described [10,26].

Results

Circulating Neutrophil Degranulation

The neutrophil MPO content was assessed by flow cytometry and by confocal microscopy in whole blood samples fixed and labeled without any further manipulation. The normal range of neutrophil MPO content, preliminarily defined in our laboratory on the basis of the results obtained in 50 healthy subjects, ranged between 98 and 203 arbitrary units of mean fluorescence intensity (MFI) detected within the neutrophil (CD66b+) population. Background signal (after complete neutrophil MPO depletion by stimulation of whole blood samples with fMLP) was 8–22 MFI. Thus the 23–97 MFI range was used to define neutrophils with low MPO content (Figure S1).

The average neutrophil MPO content in healthy donors (149.3±3.4 MFI) was stable: it did not substantially change with age (age range 20–80 years) or gender (Table S1). The MPO content in contrast was dramatically reduced in patients with ACS (Table 4, Figure 1 and Figure S1), but it was unaffected, either before or after PCI, in patients with CSA who had a greater burden of coronary atherosclerosis than ACS patients (Table 1 and 4).

Neutrophils from STEMI patients had a significantly greater burden of coronary atherosclerosis than ACS patients (Table 1, Figure 1, panels A-D, Table 4).

The simultaneous occurrence of three different sub-populations of neutrophils was confirmed by confocal microscopy (Figure 1, panels B). Nine of 21 NSTEMI patients also had a trimodal pattern of MPO expression. By contrast, neutrophils from patients

Table 4. Neutrophil myeloperoxidase (MPO) content.

|                  | n   | Neutrophils count (×105/μL) | Average MPO content (MFI) | MPO depletion (% neutrophils) | Low MPO content (% neutrophils) | Normal MPO content (% neutrophils) | Trimodal MPO content (N/total) |
|------------------|-----|-----------------------------|---------------------------|-----------------------------|---------------------------------|------------------------------------|---------------------------------|
| Healthy volunteers | 138 | 3.6±0.8                     | 149.3±14.0                | <1                          | 1.2±0.9                          | 96.4±1.4                           | 0/138                           |
| ACS              |     |                             |                           |                             |                                 |                                    |                                 |
| STEMI            | 33  | 9.2±0.6                     | 56.1±5.8                  | 21.5±5.4                    | 45.6±7.2                       | 30.6±7.1                          | 32/33                           |
| NSTEMI           | 21  | 7.9±0.5                     | 73.2±10.4                 | 11.8±4.1                    | 56.9±6.5                       | 29.9±6.2                          | 9/21                            |
| UA               | 15  | 5.2±0.5                     | 91.7±12.0                 | <1                          | 60.0±6.2                       | 36.5±11.4                         | 0/15                            |
| CSA              |     |                             |                           |                             |                                 |                                    |                                 |
| before PCI       | 69  | 4.0±2.8                     | 134.1±26.9                | <1                          | 5.8±1.6                         | 91.2±4.7                          | 0/54                            |
| after PCI        | 15  | 3.8±0.3                     | 133.1±8.7                 | <1                          | 11.8±4.0                        | 87.5±5.7                          | 0/15                            |
| Septal Alcholization |     |                             |                           |                             |                                 |                                    |                                 |
| before            | 4   | 3.6±0.7                     | 131.3±11.8                | <1                          | 4.3±1.8                         | 92.8±2.8                          | 0/4                             |
| after             | 4   | 4.8±0.2                     | 170.8±10.9                | <1                          | 2.5±1.3                         | 97.2±1.8                          | 0/4                             |
| Acute traumatic bone fracture | 5   | 12.8±0.3                   | 116.2±12.8                | <1                          | 23.9±9.1                        | 75.2±9.3                          | 0/5                             |
| ANCA-associated small-vessel vasculitis | 11  | 7.8±1.4                     | 87.9±9.9                  | <1                          | 59.6±8.3                        | 36.5±8.4                          | 0/11                            |
| Rheumatoid Arthritis | 11  | 7.6±0.9                     | 80.0±11.7                 | <1                          | 74.5±9.1                        | 19.1±3.8                          | 0/11                            |
| Giant Cell Arthritis | 8   | 5.1±0.9                     | 84.4±18.5                 | <1                          | 16.0±11.3                       | 80.4±8.6                          | 0/8                             |
| Polymyalgia Rheumatica | 8   | 5.7±1.5                     | 49.6±14.9                 | <1                          | 63.2±19.3                       | 22.3±7.1                          | 0/8                             |
| Sepsis           | 7   | 22.2±4.4                    | 61.9±8.8                  | <1                          | 97.0±3.5                        | 2.0±2.1                           | 0/7                             |

MPO = myeloperoxidase, MFI = mean fluorescence intensity revealed within neutrophils (CD45+, CD66b+, CD14− cells). ACS: acute coronary syndromes. STEMI: segment Y elevated myocardial infarction. NSTEMI: no STEMI. UA: unstable angina. ANCA: anti neutrophils cytoplasmatic antigens. Statistically different from the healthy volunteers: *P<0.05; †P<0.01 and ‡P<0.001.

doi:10.1371/journal.pone.0039484.t004
with unstable angina had a homogeneously reduced unimodal expression of MPO (Table 4). Neutrophil degranulation was significantly associated with up-regulation and transactivation of the leukocyte β2 integrin (CD11b/CD18) Mac-1 (Table 5).

CD16 expression is reduced or absent in apoptotic neutrophils ([29,30,31]). The possibility that complete MPO depletion observed in AMI patients was due to neutrophil apoptosis was ruled out by the observation that 94.1±1.8% of neutrophils with complete MPO depletion in 15 consecutive AMI patients had a normal expression of CD16 (859.1±22.2 MFI) compared to that of healthy matched controls (96.6±1.3%, 855.2±15.4 MFI). At variance, the subpopulation of neutrophils with normal MPO content was positive for MRP8.14, possibly reflecting its recent release into the bloodstream (Table 5).

Figure 1. Heterogeneity of myeloperoxidase content in circulating neutrophils from patients with acute myocardial infarction is associated to platelet adhesion and activation. Intracellular MPO content in circulating neutrophils and platelet-neutrophil heterotypic aggregates were evaluated in whole blood samples by four-color flow cytometry. Venous blood samples were obtained within the first 6 hours of onset of symptoms. For confocal determinations, monoclonal antibodies against MPO were labeled with Alexa Fluor 488 (green) and against platelet glycoprotein Ib with Alexa Fluor 546 (red). Hoechst (blue) was used for counterstaining of nuclei. Panel A. Representative confocal images illustrate the MPO (green) content observed in circulating neutrophils of a patient with chronic stable angina. Panel B. Representative confocal images illustrate the heterogeneity in the MPO (green) content observed in circulating neutrophils of a patient with acute myocardial infarction. Panel C-D. The cytofluorimetric histogram shows the trimodal pattern MPO-associated distribution (black) in AMI but not in CSA, vs isotype control (white). Panel E. Confocal images of neutrophils with complete MPO depletion, low or normal MPO content. Results are the mean value ± SEM of heterotypic aggregates observed in each neutrophil subpopulation. Panel F: confocal microscopy of aggregates between platelet (red) and degranulated neutrophils from a representative patient with AMI. Panel G. Correlation analysis indicates the association between platelet activation and neutrophil myeloperoxidase content in patients with AMI: platelet P-selectin expression (% of CD61+ cells, y axis) are plotted against the neutrophil intracellular MPO content (MFI-within CD66b+ cells, x axis; R = 0.6, P<0.0001).

doi:10.1371/journal.pone.0039484.g001
## Table 5. Markers of cellular activation.

|                      | n  | Neutrophil Mac-1 transactivation (% CD66b) | Monocyte Mac-1 transactivation (% CD14) | Neutrophil MRP 8.14 (% CD66b) | Platelet P-selectin expression (% CD61) | Platelet – neutrophil aggregates (% CD66b) | Platelet – monocyte aggregates (% CD14) |
|----------------------|----|------------------------------------------|----------------------------------------|-------------------------------|----------------------------------------|------------------------------------------|------------------------------------------|
| Healthy volunteers   | 138| 9.8±1.1                                  | 7.1±3.3                                | 3.1±1.0                       | 6.8±0.6                                | 7.3±0.8                                  | 4.3±1.2                                  |
| ACS                  |    |                                          |                                        |                               |                                        |                                          |                                          |
| STEMI                | 33 | 47.6±5.2                                 | 56.0±11.1                              | 31.4±5.2                      | 22.6±2.1                               | 18.1±1.4                                | 16.0±1.9                                 |
| NSTEMI               | 21 | 38.2±9.8                                 | 41.0±8.5                               | 27.9±3.1                      | 23.3±3.5                               | 152±1.8                                 | 15.9±2.0                                 |
| UA                   | 15 | 38.4±9.2                                 | 39.1±9.1                               | 20.1±5.3                      | 14.3±2.5                               | 122±1.6                                 | 11.0±1.5                                 |
| CSA                  |    |                                          |                                        |                               |                                        |                                          |                                          |
| before PCI           | 69 | 9.4±1.3                                  | 6.1±0.7                                | 4.1±1.6                       | 7.4±0.9                                | 6.7±0.5                                  | 4.4±0.4                                  |
| after PCI            | 15 | 9.0±2.1                                  | 9.3±1.1                                | 4.9±2.0                       | 7.7±1.0                                | 8.2±0.9                                  | 4.1±0.5                                  |
| Septal alcoholization|    |                                          |                                        |                               |                                        |                                          |                                          |
| before              | 4  | 4.9±0.6                                  | 4.6±0.5                                | 6.3±2.6                       | 10.4±4.2                               | 138±2.9                                 | 10.6±0.6                                 |
| after               | 4  | 10.3±3.1                                 | 9.8±4.2                                | 12.9±4.1                      | 8.3±2.2                                | 8.1±4.0                                  | 6.4±3.9                                  |
| Acute traumatic bone fracture | 5 | 10.1±3.2                                 | 5.9±1.1                                | 23±1.2                       | 6.9±3.8                                | 6.7±4.7                                  | 4.8±3.8                                  |
| ANCA-associated small-vessel vasculitis | 11 | 44.2±5.5                               | 37.9±4.5                               | 38.2±3.2                      | 24.4±5.2                               | 8.3±1.8                                  | 6.3±1.4                                  |
| Rheumatoid Arthritis | 11 | 52.1±3.7                                | 49.1±7.1                               | 21.6±6.9                      | 25.6±3.4                               | 157±26                                  | 8.7±2.0*                                 |
| Giant Cell Arteritis | 8  | n.d.                                     | n.d.                                   | nd                           | 18.3±3.4                               | 18.1±3.9                                | 12.5±2.2*                                |
| Polymyalgia Rheumatica | 8 | n.d.                                     | n.d.                                   | nd                           | 9.1±3.5                                | 133±21.6                                | 7.4±1.5*                                 |
| Sepsis               | 7  | 66.2±11.1                                | 643±96.5                               | 48.2±9.1                      | 14.4±2.6                               | 141±59*                                 | 4.4±1.1                                  |

ACS: acute coronary syndromes. STEMI: segment T elevated myocardial infarction. NSTEMI: no STEMI. UA: unstable angina. ANCA: anti neutrophils cytoplasmatic antibodies. n.d = not determined. Statistically different from the healthy volunteers * = P<0.05; **P<0.01 and ***P<0.001. doi:10.1371/journal.pone.0039484.t005
Neutrophil Activation in AMI

Figure 2. Time course of leukocyte and platelet activation in patients and controls. 36 patients with acute myocardial infarction were studied before any therapeutic treatment and re-studied at different times on PCI. Results (expressed as mean ± SEM) were compared with 69 patients with chronic stable angina candidates (CSA) for PCI and 138 healthy donors. Determinations were performed by flow cytometry, with the exception of troponin I, as described in material and methods. Y axis: serum troponin (Panel A), granulocyte cell counts (panel B), fraction of circulating neutrophils with complete myeloperoxidase (MPO) depletion (Panel C), average of neutrophil MPO content (Panel D), fraction of platelet expressing P-selectin (Panel E), the fraction of platelet-neutrophils heterotypic aggregates (Panel F), fraction of platelet-monocyte heterotypic aggregates (Panel G). * = P<0.05; ** = P<0.01 (both respect to CSA and healthy donors) were determined by ANOVA followed Bonferroni test.

doi:10.1371/journal.pone.0039484.g002

Time Course of MPO Depletion

The percentage of neutrophils with a complete MPO depletion was greatest in STEMI patients studied within 4 hours, intermediate in those studied within 4–8 hours and lower in samples collected 8–12 hours after the onset of symptoms (in all cases prior to any treatment) (Figure 2). The average neutrophil MPO content returned to normal values within 24–36 hours (Figure 2).

Neutrophil activation was associated with monocyte activation, as indicated by CD11b/CD18 up-regulation and transactivation (Table 5). In all ACS patients a significant increase of platelet-leukocyte (neutrophils and monocytes) heterotypic aggregates was observed (Table 5, Figure 1, panels E-F and Figure 2). This was maximal for neutrophils in samples taken early after the onset of symptoms and disappeared within 24 hours (Figure 2, panel F). Monocyte activation persisted after 48 hour, possibly because of monocyte longer life span (Figure 2, panel G). Circulating platelets were also activated, as indicated by the up-regulation of surface P-selectin (Table 5). The time course of platelet activation was similar to that of neutrophils (Figure 2, panel E).

Neutrophil Activation in Systemic Inflammatory Conditions

To investigate whether the trimodal pattern of MPO expression observed in the very early phases of STEMI was also present in other systemic inflammatory syndromes, we studied conditions of leukocyte activation associated with microbial infection (sepsis) or with self-sustained systemic inflammation (rheumatoid arthritis, ANCA-associated small-vessel vasculitis, polymyalgia rheumatica and giant cell arteritis) (Tables 2 and 3). A reduced neutrophil MPO content was observed in all these clinical conditions. The trimodal pattern of MPO expression observed in AMI patients was not detectable in any of the other conditions, regardless of: i) increased peripheral neutrophil count in patients with acute traumatic bone fracture (12.8±0.3 neutrophils/μL) and sepsis (22.2±4.4 neutrophils/μL); ii) the presence of ANCA, known to amplify the activation of neutrophils [12], and iii) the massive elevation in inflammatory markers of patients with giant cell arteritis, polymyalgia rheumatica or rheumatoid arthritis (Table 4). A normal MPO content was observed in the four patients undergoing septal alcoholization; taken together with the normal MPO content observed in patients with bone fracture these data strongly suggest that tissue necrosis per se is not responsible for the trimodal pattern of MPO expression observed in AMI patients (Table 4).

Neutrophils MPO Depletion and Platelet Activation

As platelet activation has been associated to neutrophil degranulation [10,11,28] we have also assessed platelet expression of P-selectin and the presence of platelet-neutrophil heterotypic aggregates in STEMI and NSTEMI patients (Figure 1, panel G and Table 5). At covariance analysis after logarithmic transformation of data the percentage of platelets expressing P-selectin was an independent variable (p = 0.00016) for platelet-neutrophil heterotypic aggregates and neutrophil MPO content. Further-}

more, the percentage of platelets expressing P-selectin was inversely correlated with the average neutrophil MPO content (r = −0.75, p<0.001) and directly correlated with the percentage of neutrophils with complete MPO depletion (r = 0.57, p<0.001) in AMI patients (Figure 1, panel G). Accordingly, the fraction of platelet-neutrophil heterotypic aggregates correlated inversely with the average MPO content (r = −0.53, p<0.0005) and directly with the proportion of neutrophils with complete MPO depletion (r = 0.41, p<0.001).

Platelet and neutrophil activation were associated, because the extent of platelets adhesion (heterotypic aggregates) was significantly higher for neutrophils with complete MPO depletion than with low MPO content. Panels E-F of Figure 1 depict the analysis of patients samples by confocal microscopy and flow cytometry simultaneously: only very few adherent platelets were observed in neutrophils with normal MPO content.

Patients with rheumatoid arthritis and giant cell arteritis showed a variable proportion of neutrophils with adherent platelets, with an inverse correlation between the percentage of platelet-neutrophil heterotypic aggregates and the neutrophil MPO content (r = 0.59, P<0.01). No correlation was found in patients with ANCA- associated small vessel vasculitis or with severe sepsis.

Platelet P-selectin Expression is Required for MPO Depletion in Experimental Animals

We have injected purified platelets, either activated or resting, in the tail vein of C57BL/6 mice. Blood was sampled at 1, 2, 3 and 24 hours after platelet infusion and the neutrophil MPO content was determined by flow cytometry. One hour after the injection of activated platelets the percentage of platelets expressing P-selectin increased from 2.2±1.3% to 29.0±1.1% (p<0.001) and 46.0±5.5% of circulating neutrophils showed complete MPO depletion (Figure 3). The fraction of platelet-neutrophil heterotypic aggregates increased from 5.7±2.1 to 36.2±2.3% (p<0.001) while the neutrophil MPO content decreased from 58.2±1.6 to 38.9±1.0 (p<0.001); (Figure 3, panel A). No significant change in any of these parameters was observed in mice injected with activated platelets from P-sel-/− mice (Figure 3, panel B), or with resting platelets (Figure 3, panel C).

Discussion

Our results indicate that neutrophil activation is substantially greater in patients with STEMI, compared with those with non STEMI or unstable angina. Neutrophil activation is associated with increased neutrophil counts and with a larger fraction of circulating neutrophils with features reflecting recent origin from the bone marrow. Of importance, a fraction of neutrophils is not degranulated in STEMI patients, which may reflect an abnormal response to activating stimuli or, more likely, a population of circulating neutrophils never exposed to stimuli restricted within a specific vascular district. The acute arterial occlusion that is a hallmark of myocardial infarction could contribute in these patients to protect neutrophils newly emerged from the bone marrow, preventing MPO release.
Neutrophil activation is strictly linked to systemic inflammation, because microbial and endogenous triggers of inflammation are primarily recognized by innate receptors which are non clonally distributed on circulating leukocytes. Not surprisingly, a normal MPO content was observed in only 2% of neutrophils from patients with severe sepsis. Mobilization of the neutrophil effector action, and specifically the release of the granule content, could in principle jeopardize the integrity of the vessel wall [2,3,20,32,33], and several regulatory feedback mechanisms regulate the extent of neutrophil activation in the peripheral blood [34]. Accordingly, we failed to detect the trimodal pattern of MPO expression in any of the self-sustaining inflammatory conditions investigated, where the original noxa is likely to be persistent, but possibly expressed at a lower extent compared to STEMI.

A low neutrophil MPO content was found in patients presenting with very low levels of troponin I, a well-accepted marker of myocardial cell death (Table 1, Figure 2A), suggesting that neutrophil activation is an early event in patients with evolving AMI. From a pathophysiological perspective, it is intriguing to speculate whether neutrophil activation may even precede myocardial injury and may be causally involved in plaque rupture [2,3,20]. It cannot be excluded that the systemic release of markers of tissue injury occurs at a later time compared to MPO release. However, the marked differences in time course raise the possibility that neutrophil activation associated to myocardial necrosis may represent a consequence or even a component of the evolving plaque rupture. Other studies speculated on this tenet and neutrophil degranulation and the consensual increase of neutrophil-derived proteases in plasma were found in patients with unstable angina and acute myocardial infarction.

To address this issue, we have verified the effect of percutaneous transluminal septal myocardial ablation, a procedure based on the injection of alcohol into the septal branches of the coronary artery that feed the enlarged interventricular septum of patients with hypertrophic obstructive cardiomyopathy. This procedure results in the synchronized death of myocardicocytes, with substantial and swift increase of troponin I blood levels and represents a unique human model of iatrogenic myocardial necrosis in vivo [24,36]. We did not detect any MPO content reduction. The result, if combined with the conserved MPO content of neutrophils after PCI or acute traumatic fracture of the bone, makes unlikely the possibility that necrosis per se is sufficient to account for MPO depletion. Of interest, in none of these circumstances we have observed increased levels P-selectin or of P-selectin dependent events, such as heterotypic platelet-leukocyte aggregates.

Moreover, patients with CSA had substantial atherosclerosis of coronary arteries, but circulating neutrophils had a relatively normal MPO content. This observation may suggest that atherosclerosis per se is not directly involved in MPO depletion.
Neutrophil Activation in AMI

which appears to be specifically associated with acute coronary syndromes.

The persistence of high plasmatic levels of MPO can identify patients with high risk of complications [32,37]. This study to our knowledge is the first directly comparing the time courses of leukocyte activation and myocardial tissue damage. This is of importance because systemic leukocyte activation is widely believed to occur as a consequence of myocardial tissue injury rather than of plaque instability preceding the myocardial infarction. Our data now indicate that this perception might underestimate the cross talk between neutrophils and activated platelets in acute coronary syndromes and well fit with the previous observations of the widespread activation of neutrophils across the coronary vascular bed [38].

We have observed a tight correlation between indices of platelet-neutrophil interaction: the characteristic feature of MPO content, together with the results obtained in the experimental animal model, suggest that neutrophil degranulation is due to their interaction with activated platelets. Indeed, previous experimental models support the concept that P-selectin is able to induce neutrophil activation and degranulation [9,10,11,28,39]. The time course of P-selectin expression observed by us and others [1,10,11,17] and the evidence that platelet P-selectin is able in vitro [10,11,28] and in vivo to prompt the degranulation of neutrophil are in agreement with this model. Our experimental evidences indicate that a burst of P-selectin expression (such as that induced in vivo by the injection of activated wild-type but not P-selectin knock-out platelets) reproduces the extreme and transient neutrophil MPO depletion that we have observed in patients with acute myocardial infarction. These observations may have diagnostic and pathogenetic implications.

Neutrophil MPO complete depletion occurs when platelets express P-selectin rather abruptly, like it occurs in patients with AMI, in which a sudden and transient burst of platelet activation occurs. This is the scenario that we mimic in the mouse, in which we directly inject in the blood P-selectin expressing platelets. In contrast, platelets of patients with unstable angina or with other systemic inflammatory syndromes are characterized by a persistent, waxing and waning P-selectin expression. This is likely to recruit adaptive mechanisms that limit the paroxysmal neutrophil activation and thus protect the integrity of vessel walls. Further studies are necessary to verify this possibility.

The transient nature of neutrophil activation in patients with AMI could be explained by rapid loss of P-selectin as a consequence of active proteolysis [1,39] by the proteases derived from the neutrophils and by the inhibitory effect of pentraxin 3 released by neutrophils as consequence of activated platelet adhesion [8,11,40], which has been shown to interfere with neutrophil functions in vitro and in vivo [41]. Moreover, the clearance of activated platelets represents a further likely mechanism involved in the swift termination of neutrophil activation [7,8,10,26]. The actual contribution of these non-mutually exclusive mechanisms remains to be established.

Supporting Information

Figure S1 Intracellular MPO content in resting and stimulated neutrophils assessed by confocal microscopy and flow cytometry. Whole blood samples from healthy donors were stimulated as described in material and methods. For confocal determinations, monoclonal antibodies against MPO were labeled with Alexa Fluor 488 (green) and DNA labeled with Hoechst (blue). For flow cytometry, samples were labeled with mAbs against CD66b (specific for neutrophils) and after permeabilization with mAbs against MPO.

Table S1 MFI = mean fluorescence intensity.

Author Contributions

Conceived and designed the experiments: NM PR-Q VE AAM AM. Performed the experiments: NM LC MB. Analyzed the data: NM VE CG MG. Contributed reagents/materials/analysis tools: VE CG MD FF. Wrote the paper: NM PR-Q VE AAM AM. For patients with acute coronary syndromes and chronic stable angina: MG MD FF MB. For patients with severe septic ADA. For patients with autoimmune diseases: MB EB AAM. For sex-ag- matched healthy controls: GG FF MS MC MB. For animal models: LC.

References

1. Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI (2001) Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 104: 1533–1537.
2. Ferrante G, Nakano M, Prati F, Niccoli G, Mallus MT, et al. (2010) High levels of systemic myeloperoxidase are associated with coronary plaque erosion in patients with acute coronary syndromes: a clinicopathological study. Circulation 122: 2503–2513.
3. Goldmann BU, Rudolph V, Rudolph TK, Holle AK, Hillebrandt M, et al. (2009) Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free Radiol Biol Med 47: 79–83.
4. Weber C, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerotic lesions from mouse models. Nat Rev Immunol 8: 802–815.
5. Hidalgo A, Chang J, Jang JE, Feurde AJ, Chiang EY, et al. (2009) Heterotypic interactions enabled by polarized neutrophil microdomains mediate thrombin-mediated inflammatory injury. Nat Med 15: 384–391.
6. Manfredi AA, Rovere-Querini P (2010) The mitochondrion-a Trojan horse that kicks off inflammation? N Engl J Med 362: 2132–2134.
7. Manfredi AA, Rovere-Querini P, Maugeri N (2010) Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol 17: 3–8.
8. Maugeri N, Baldini M, Ramirez GA, Rovere-Querini P, Manfredi AA (2012) Platelets-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases. Thromb Res 129(3): 267–73.
9. Maugeri N, Baldini M, Rovere-Querini P, Maseri A, Sabbadini MG, et al. (2009) Leukocyte and platelet activation in patients with giant cell arteritis and polymyalgia rheumatica: a clue to thromboembolic risks? Autoimmunity 42: 380–388.
10. Maugeri N, Rovere-Querini P, Evangelista V, Covino C, Capobianco A, et al. (2009) Neutrophil phagocytose activated platelets in vivo: a phosphatidylserine, P-selectin, and 82 integrin-dependent cell clearance program. Blood 113: 5247–5265.
11. Maugeri N, Rovere-Querini P, Slavich M, Coppi G, Doni A, et al. (2011) Early and transient release of leukocyte pentraxin 3 during acute myocardial infarction. J Immunol 187: 970–979.
12. Maugeri N, Rovere-Querini P, Baldini M, Sabbadini MG, Manfredi AA (2009) Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol 156: 395–404.
13. Adlbrecht C, Bonderman D, Plass C, Jakowski J, Beran G, et al. (2007) Active endothelin is an important vasoconstrictor in acute coronary thrombus. Thromb Haemost 97: 642–649.
14. Foroni LA, Maugeri N, Rovere-Querini P, Calabrese A, Ammirati E, et al. (2009) Anti-inflammatory action of apoptotic cells in patients with acute coronary syndromes. Atherosclerosis 205: 391–395.
15. Furie B, Furie BC (2008) Mechanisms of thrombus formation. N Engl J Med 359: 939–949.
16. Palharcia T, Lohb R, Furie BC, Aronowicz M, Benjamin C, et al. (1992) Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature 359: 848–851.
17. Furman MI, Barnard MR, Krueger LA, Fox ML, Shihale EA, et al. (2001) Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 38: 1002–1006.
18. Sakai T, Inoue S, Takai M, Ogawa G, Hamazaki Y, et al. (2011) Activated inflammatory cells participate in thrombus size through tissue factor and plasminogen activator inhibitor-1 in acute coronary syndrome: Immunohistochemical analysis. Thromb Res 127: 443–449.

19. Dietelmaier K, Adlibrechi C, Jakowitsch J, Winkler S, Dunkler D, et al. (2009) Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 102: 564–572.

20. Apple FS, Smith SW, Pearce LA, Schulz KM, Ler R, et al. (2011) Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations. Clin Chem 57: 603–608.

21. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaha I, et al. (2010) Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330: 362–366.

22. Dominguez-Rodriguez A, Ahreu-Gonzalez P (2011) Current role of myeloperoxidase in routine clinical practice. Expert Rev Cardiovasc Ther 9: 223–230.

23. Evangelista V, Pamulakar Z, Piccoli A, Manarini S, Delfelio G, et al. (2007) Src family kinases mediate neutrophil adhesion to adherent platelets. Blood 109: 2461–2469.

24. Airoldi F, Di Mario C, Dharmaikar A, Tzifos V, et al. (2000) Progression of outflow gradient and septum thickness after percutaneous alcoholization of the interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J 1: 200–206.

25. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315–324.

26. Maugeti N, Malato S, Femia EA, Pugliano M, Campana L, et al. (2000) Prevention of platelet-polymerphomuclear leukocyte interactions: new clues to the antithrombotic properties of pparaparin, a low molecular weight heparin. Haematologica 90: 833–839.

27. Garlichs CD, Eskali S, Cicha I, Schroeder A, Walzog B, et al. (2004) Delay of neutrophil apoptosis in acute coronary syndromes. J Leukoc Biol 75: 825–835.

28. Dransfield I, Buckle AM, Savill JS, McDowall T, Haslett C, et al. (1994) Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma III) expression. J Immunol 153: 1254–1263.

29. Tang WH, Kaiz R, Broxman ML, Aviles RJ, Tracy RP, et al. (2009) Usefulness of myeloperoxidase levels in healthy elderly subjects to predict risk of developing heart failure. Am J Cardiol 103: 1269–1274.

30. Apple FS, Pearce LA, Chung A, Ler R, Murakami MM (2007) Platelet-leukocyte interactions for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin Chem 53: 874–881.

31. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, et al. (2002) Widespread coronary inflammation in unstable angina. N Engl J Med 347: 5–12.

32. Gardiner EE, De Luca M, McNally T, Michelson AD, Andresen RK, et al. (2000) Clearance of circulating activated platelets in polychromatina vera and essential thrombocytopenia. Blood 110: 3359–3366.

33. Rojas G, Gottschalk RF, Akigishi TW, Staunton DE. (2001) CD11b activation epitopes induced by leukocyte activation. J Immunol 167: 6133–6122.

34. Baldini M, Maugeri N, Ramirez GA, Giacomassi C, Castiglioni A, et al. (2012) Prevention of platelet-polymerphonuclear leukocyte interactions: new clues to the antithrombotic properties of pparaparin, a low molecular weight heparin. Haematologica 90: 833–839.

35. Mantovani A, Casatella MA, Costantini C, Zavallone C (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11: 519–531.